Preclinical models demonstrate tumor stasis in ATM negative pancreatic cancer using alnodesertib and irinotecan, suggesting a promising new treatment strategy.
Key Points
To evaluate the efficacy of alnodesertib in combination with irinotecan in ATM null pancreatic cancer models.
Conducted mechanistic preclinical studies in in vitro and in vivo ATM negative pancreatic cancer models.
Used CDX and PDX models to assess tumor response to the combination therapy.
Examined the effects of targeting ATR and inducing replication stress.
The combination therapy induced tumor stasis or regression in all preclinical models studied.
Response rates of up to 50% were noted across eight tumor types.
Pancreatic cancer showed high sensitivity to the new treatment modality.